Pertuzumab-Biosimilar erhält als erstes Biosimilar positive CHMP-Stellungnahme unter dem neuen maßgeschneiderten Entwicklungsansatz der EMA
BENGALURU, Indien, 22. September 2026 /PRNewswire/ -- Biocon Biologics Limited, eine hundertprozentige Tochtergesellschaft von Biocon Limited (BSE: 532523) (NSE: BIOCON), gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) eine...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Farewell Launches Novel, Emotionally-Adaptive AI Platform for Life Transitions
- WILD ABOUT SPROUTS DELIVERS OUT-OF-THIS-WORLD GROWTH AS RÄFOODS' LIVING NUTRITION STRATEGY TAKES ROOT
- IAB Releases Measurement Services Addendum v1.0 for Public Comment
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →